Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront HSCT versus immunosuppressive therapy in early diffuse cutaneous systemic sclerosis
NL-OMON60431Phase 4Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclophosphamide in diffuse cutaneous systemic sclerosis (dcSSc) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Global Rank Composite Score. Started Aug 2020; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NL-OMON60431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60431.